이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mustang Bio 관리

관리 기준 확인 4/4

Mustang Bio's CEO는 Manny Litchman, Apr2017 에 임명되었습니다 의 임기는 7.17 년입니다. 총 연간 보상은 $ 501.84K, 95.8% 로 구성됩니다. 95.8% 급여 및 4.2% 보너스(회사 주식 및 옵션 포함). 는 $ 70.58K 가치에 해당하는 회사 주식의 0.29% 직접 소유합니다. 70.58K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 8 년입니다.

주요 정보

Manny Litchman

최고 경영자

US$501.8k

총 보상

CEO 급여 비율	95.8%
CEO 임기	7.5yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28

CEO 보상 분석

Manny Litchman 의 보수는 Mustang Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$32m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$502k	US$481k	-US$52m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$72m
Mar 31 2023	n/a	n/a	-US$74m
Dec 31 2022	US$636k	US$448k	-US$78m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$76m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$885k	US$450k	-US$66m
Sep 30 2021	n/a	n/a	-US$67m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$1m	US$430k	-US$60m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$53m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$517k	US$415k	-US$46m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$39m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$606k	US$403k	-US$31m
Sep 30 2018	n/a	n/a	-US$34m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$34m
Dec 31 2017	US$6m	US$267k	-US$31m

보상 대 시장: Manny 의 총 보상 ($USD 501.84K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Manny 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Manny Litchman (70 yo)

7.5yrs

테뉴어

US$501,838

보상

Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio, Inc. since April 24, 2017 and served as Interim Chief Financial Officer since Dec...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Weiss	Executive Chairman	9.4yrs	US$110.00k	0.044% $ 3.6k
Manuel Litchman	President	7.5yrs	US$501.84k	0.21% $ 17.0k
James Murphy	Interim Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Peter Carney	Controller & Interim Chief Accounting Officer	less than a year	데이터 없음	0.0067% $ 558.3
Matthew Wein	VP & General Counsel	3.1yrs	데이터 없음	데이터 없음
Debra Manning	Senior VP & Head of Human Resources	5.8yrs	데이터 없음	데이터 없음
Lynn Bayless	VP & Head of Regulatory Affairs	4.6yrs	데이터 없음	데이터 없음
Bruce Dezube	Senior VP & Head of Clinical Development	3.3yrs	데이터 없음	데이터 없음
Greg Furrow	Chief Quality Officer	1.8yrs	데이터 없음	데이터 없음
Richard Bodmer	Head of CMC Development	2.2yrs	데이터 없음	데이터 없음
Robert Sexton	VP and Head of Program & Alliance Leadership	1.8yrs	데이터 없음	데이터 없음
Kerry Biron	VP & Head of Clinical Operations	1.8yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 관리: MBIO 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Weiss	Executive Chairman	9.4yrs	US$110.00k	0.044% $ 3.6k
Manuel Litchman	President	7.5yrs	US$501.84k	0.21% $ 17.0k
Lindsay Rosenwald	Non-Executive Director	9.6yrs	US$100.00k	0.073% $ 6.1k
Michael Zelefsky	Independent Director	7.3yrs	US$100.00k	0.051% $ 4.2k
Neil Herskowitz	Independent & Non-Executive Director	9.2yrs	US$100.00k	0.053% $ 4.4k
Adam Chill	Independent Director	7.3yrs	US$110.00k	0.052% $ 4.3k

8.3yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: MBIO 의 이사회는 경험(평균 재직 기간 8 년)으로 간주됩니다.

Mustang Bio 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Insufficient new directors

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

President recently bought US$251k worth of stock

Recent updates

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

New major risk - Shareholder dilution

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Price target decreased by 43% to US$10.00

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

New minor risk - Share price stability

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

New major risk - Financial position

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Price target decreased by 29% to US$13.00

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Price target decreased to US$5.00

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Price target decreased to US$7.40

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio: The Market Is Missing This Opportunity

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Price target decreased to US$8.40

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Price target decreased to US$9.80

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

President recently bought US$251k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Checking Back In On Mustang Bio

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy